Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 02, 2007. The report serves as a notification to the market regarding the Company's total voting rights and capital structure as of September 28, 2007, in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a capital structure notification.
| Metric | Value |
|---|---|
| Issued Share Capital | 6,024,125,364 Ordinary shares of 25p each |
| Treasury Shares | 415,539,158 Ordinary shares |
| Total Voting Rights | 5,608,586,206 |
Material Changes
The filing text does not provide a clear value or description of material changes versus the prior comparable period. The document focuses solely on the current capital count.
Guidance, Outlook, and Risks
The filing text does not provide clear values for guidance, outlook, management commentary, risks, contingencies, or unusual items. The primary purpose is to inform shareholders of the denominator to be used for calculating notification thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of voting rights (5,608,586,206) for compliance with disclosure thresholds.
- Confirm the number of shares held in Treasury (415,539,158) to understand the free float.
- Note that this filing does not contain financial performance data; refer to Form 20-F for financial results.